Northwestern Mutual Wealth Management Co. Purchases 24,462 Shares of Zoetis Inc. $ZTS

Key Points

• Northwestern Mutual Wealth Management Co. increased its stake in Zoetis Inc. by 8.3%, now owning 320,203 shares valued at approximately $52.7 million after acquiring an additional 24,462 shares.
• Zoetis reported a profit of $1.76 per share for the latest quarter, exceeding analyst expectations, with a revenue of $2.46 billion, marking a 4.2% year-over-year increase.
• Various institutional investors have significantly adjusted their positions in Zoetis recently, with 92.80% of the company's stock now owned by institutional investors.

Northwestern Mutual Wealth Management Co. grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 8.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 320,203 shares of the company's stock after acquiring an additional 24,462 shares during the period. Northwestern Mutual Wealth Management Co. owned 0.07% of Zoetis worth $52,721,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ZTS. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock valued at $754,000 after acquiring an additional 2,978 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Zoetis in the fourth quarter valued at approximately $216,000. First Trust Advisors LP raised its stake in shares of Zoetis by 134.8% in the fourth quarter. First Trust Advisors LP now owns 104,496 shares of the company's stock valued at $17,026,000 after acquiring an additional 59,990 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Zoetis by 11.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,627 shares of the company's stock valued at $591,000 after acquiring an additional 358 shares during the last quarter. Finally, Coppell Advisory Solutions LLC raised its stake in shares of Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock valued at $68,000 after acquiring an additional 64 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.18% of the company's stock.

Zoetis Trading Up 0.5%

ZTS opened at $156.3180 on Friday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company has a market cap of $69.28 billion, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88. The firm has a 50 day simple moving average of $153.84 and a 200 day simple moving average of $158.52. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the firm earned $1.56 EPS. Zoetis's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analysts Set New Price Targets

ZTS has been the topic of several research analyst reports. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. UBS Group decreased their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.